Valeria Fantin, Sanofi global head of oncology research
Sanofi turns to a Jennifer Doudna gene editing upstart for next-gen NK cell alliance
Big Pharmas — as well as more than a few biotechs — are on the hunt for the best, cutting-edge gene editing tech available, and today we can tell you about Sanofi’s choice.
The Paris-based giant’s head of oncology research and its chief of genomic medicine have settled on Scribe Therapeutics’ CasX editing tech for their work on NK cells. And the deal with the Jennifer Doudna spinout comes with a $25 million get-to-know-you upfront and a cool $1 billion in biobuck milestones, provided they can neatly knock down all the pins in the deal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
